Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

RYALTRIS NASAL SPRAY 600/25MCG [SIN16523P]

Active ingredients: MOMETASONE FUROATE MONOHYDRATE (MICRONIZED) EQV TO MOMETASONE FUROATE | OLOPATADINE HCL EQV TO OLOPATADINE

View product's general information
Last updated on 9 October 2026

Product Info

RYALTRIS NASAL SPRAY 600/25MCG

[SIN16523P]

Product information

Active Ingredient and Strength

MOMETASONE FUROATE MONOHYDRATE (MICRONIZED) EQV TO MOMETASONE FUROATE - 25 MCG/SPRAY
OLOPATADINE HCL EQV TO OLOPATADINE - 600 MCG/SPRAY

Dosage Form

SPRAY, SUSPENSION

Manufacturer and Country

GLENMARK PHARMACEUTICALS LIMITED (BADDI SITE) - INDIA
GLENMARK PHARMACEUTICALS LIMITED (CHHATRAPATI SAMBHAJINAGAR SITE) - INDIA

Registration Number

SIN16523P

Licence Holder

LOTUS INTERNATIONAL PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

R01AD59

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS
RYALTRIS® is indicated for the treatment of moderate to severe symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 6 years of age and older.

Dosing

DOSAGE AND ADMINISTRATION

Dosage
Adults and Adolescents (12 Years of Age and Older)
The recommended dosage of RYALTRIS® is 2 sprays in each nostril twice daily.
Children (6 to 11 Years of Age)
The recommended dosage of RYALTRIS® is 1 spray in each nostril twice daily.

Paediatric
In children 6 to 11 years of age, safety of RYALTRIS® beyond 2 weeks of use has not been assessed.
The safety and effectiveness of RYALTRIS® in paediatric patients below the age of 6 years has not been established.

Administration
Administer RYALTRIS® by the intranasal route only. Avoid spraying RYALTRIS® into the eyes or mouth.

Shake the bottle well before each use.

Priming: Prime RYALTRIS® before initial use by releasing 6 sprays. When RYALTRIS® has not been used for 14 days or more, re-prime by releasing 2 sprays or until a fine mist appears.

Missed Dose
If a single dose is missed, the next dose should be taken when it is due. A double dose should not be taken at the same time.

Contraindications

CONTRAINDICATIONS
RYALTRIS® is contraindicated for patients who:

  • Are hypersensitive to this medicine or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Qualitative and Quantitative Composition – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

  • Have untreated fungal, bacterial, or tuberculosis infections of the respiratory tract.